Published in Heart Fail Rev on March 09, 2017
Molecular mechanisms of amyloidosis. N Engl J Med (2003) 7.75
Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): a consensus opinion from the 10th International Symposium on Amyloid and Amyloidosis, Tours, France, 18-22 April 2004. Am J Hematol (2005) 5.64
Safety and efficacy of RNAi therapy for transthyretin amyloidosis. N Engl J Med (2013) 3.97
Evaluation and management of the cardiac amyloidosis. J Am Coll Cardiol (2007) 3.12
Classification of amyloidosis by laser microdissection and mass spectrometry-based proteomic analysis in clinical biopsy specimens. Blood (2009) 3.00
Superior survival in primary systemic amyloidosis patients undergoing peripheral blood stem cell transplantation: a case-control study. Blood (2004) 2.97
The clinical features of immunoglobulin light-chain (AL) amyloidosis with heart involvement. QJM (1998) 2.81
HEAVY CHAIN DISEASE- A NEW DISORDER OF SERUM GAMMA-GLOBULINS : REPORT OF THE FIRST CASE. Am J Med (1964) 2.59
A European collaborative study of treatment outcomes in 346 patients with cardiac stage III AL amyloidosis. Blood (2013) 2.38
Transthyretin-related amyloidoses and the heart: a clinical overview. Nat Rev Cardiol (2010) 1.81
Guideline of transthyretin-related hereditary amyloidosis for clinicians. Orphanet J Rare Dis (2013) 1.68
Biochemical effect of liver transplantation in two Swedish patients with familial amyloidotic polyneuropathy (FAP-met30). Clin Genet (1991) 1.60
Reliable typing of systemic amyloidoses through proteomic analysis of subcutaneous adipose tissue. Blood (2011) 1.58
Long-term effects of tafamidis for the treatment of transthyretin familial amyloid polyneuropathy. J Neurol (2013) 1.54
Predictors of survival to orthotopic heart transplant in patients with light chain amyloidosis. J Heart Lung Transplant (2013) 1.50
Outcomes of adults with restrictive cardiomyopathy after heart transplantation. J Heart Lung Transplant (2012) 1.49
Outcomes of heart transplantation for cardiac amyloidosis: subanalysis of the spanish registry for heart transplantation. Am J Transplant (2009) 1.45
Cardiac transplantation for amyloid heart disease: the United Kingdom experience. J Heart Lung Transplant (2004) 1.36
Al amyloidosis. Orphanet J Rare Dis (2012) 1.29
Sequential heart and autologous stem cell transplantation for systemic AL amyloidosis. Blood (2005) 1.22
Stem cell transplantation for the management of primary systemic amyloidosis. Am J Med (2002) 1.20
Changes in serum-free light chain rather than intact monoclonal immunoglobulin levels predicts outcome following therapy in primary amyloidosis. Am J Hematol (2011) 1.17
The 2016 International Society for Heart Lung Transplantation listing criteria for heart transplantation: A 10-year update. J Heart Lung Transplant (2016) 1.16
A prospective evaluation of the transthyretin Ile122 allele frequency in an African-American population. Amyloid (2005) 1.16
Liver Transplantation for Hereditary Transthyretin Amyloidosis: After 20 Years Still the Best Therapeutic Alternative? Transplantation (2015) 1.13
Long-term data from the Familial Amyloidotic Polyneuropathy World Transplant Registry (FAPWTR). Amyloid (2011) 1.07
Significance of the amyloidogenic transthyretin Val 122 Ile allele in African Americans in the Arteriosclerosis Risk in Communities (ARIC) and Cardiovascular Health (CHS) Studies. Am Heart J (2010) 1.07
Progression of systemic disease and reduced long-term survival in patients with cardiac amyloidosis undergoing heart transplantation. Follow-up results of a multicenter survey. Circulation (1991) 1.04
Amyloidogenicity and clinical phenotype associated with five novel mutations in apolipoprotein A-I. Am J Pathol (2011) 1.04
Outcome of heart transplantation in patients with amyloid cardiomyopathy. J Heart Lung Transplant (2005) 1.04
Cardiac transplantation followed by dose-intensive melphalan and autologous stem-cell transplantation for light chain amyloidosis and heart failure. Transplantation (2010) 1.04
Autologous stem cell transplant after heart transplant for light chain (Al) amyloid cardiomyopathy. J Heart Lung Transplant (2008) 1.03
Heart transplantation for homozygous familial transthyretin (TTR) V122I cardiac amyloidosis. Am J Transplant (2008) 1.00
Cardiac transplantation using extended-donor criteria organs for systemic amyloidosis complicated by heart failure. Transplantation (2007) 1.00
Combined heart and liver transplantation for familial amyloidotic polyneuropathy. J Thorac Cardiovasc Surg (2003) 0.97
Ten-year survival after autologous stem cell transplantation for immunoglobulin light chain amyloidosis. Cancer (2012) 0.97
Current state of combined heart-liver transplantation in the United States. J Heart Lung Transplant (2008) 0.95
A review of the United States experience with combined heart-liver transplantation. Transpl Int (2012) 0.95
Solid organ transplantation in AL amyloidosis. Am J Transplant (2010) 0.94
Stanniocalcin1 is a key mediator of amyloidogenic light chain induced cardiotoxicity. Basic Res Cardiol (2013) 0.91
Cardiac amyloidosis: where are we today? J Intern Med (2015) 0.90
Light chain amyloidosis: the heart of the problem. Haematologica (2013) 0.90
Natural history and therapy of TTR-cardiac amyloidosis: emerging disease-modifying therapies from organ transplantation to stabilizer and silencer drugs. Heart Fail Rev (2015) 0.89
Combined heart and liver transplantation for familial amyloidotic neuropathy: considerations from the hepatic point of view. Liver Transpl (2003) 0.89
The first Caucasian patient with p.Val122Ile mutated-transthyretin cardiac amyloidosis treated with isolated heart transplantation. Amyloid (2012) 0.89
Heart transplantation and cardiac amyloidosis: approach to screening and novel management strategies. J Heart Lung Transplant (2011) 0.88
AL (Light-Chain) Cardiac Amyloidosis: A Review of Diagnosis and Therapy. J Am Coll Cardiol (2016) 0.86
Heart transplantation in systemic (AL) amyloidosis: a retrospective study of eight French patients. Arch Cardiovasc Dis (2008) 0.86
Treatment options for severe cardiac amyloidosis: heart transplantation combined with chemotherapy and stem cell transplantation for patients with AL-amyloidosis and heart and liver transplantation for patients with ATTR-amyloidosis. Eur J Cardiothorac Surg (2007) 0.86
Combined heart and liver transplantation: a single-center experience. Transplantation (2009) 0.84
Outcomes after heart transplantation for amyloid cardiomyopathy in the modern era. Am J Transplant (2015) 0.84
Heart transplantation in patients with amyloidosis: single-center experience. Transplant Proc (2004) 0.83
Heart. Am J Transplant (2016) 0.83
Heart transplantation for cardiac amyloidosis: successful one-year outcome despite recurrence of the disease. J Heart Transplant (1988) 0.83
Natural History of Wild-Type Transthyretin Cardiac Amyloidosis and Risk Stratification Using a Novel Staging System. J Am Coll Cardiol (2016) 0.82
Cardiac transplantation for AL amyloidosis. BMJ (1994) 0.82
Staged heart transplantation and chemotherapy as a treatment option in patients with severe cardiac light-chain amyloidosis. Eur J Heart Fail (2009) 0.82
Liver transplantation and combined liver-heart transplantation in patients with familial amyloid polyneuropathy: a single-center experience. Liver Transpl (2010) 0.81
Gamma heavy chain disease in a patient with diabetes and chronic renal insufficiency: diagnostic assessment of the heavy chain fragment. J Clin Lab Anal (2008) 0.81
Heart transplantation and end-stage cardiac amyloidosis: a review and approach to evaluation and management. Methodist Debakey Cardiovasc J (2012) 0.81
Orthotopic liver transplantation for hepatic-based metabolic disorders. Transpl Int (1995) 0.81
Survival After Transplantation in Patients With Mutations Other Than Val30Met: Extracts From the FAP World Transplant Registry. Transplantation (2016) 0.81
Hypertrophic spinal pachymeningitis associated with heavy-chain disease. Case report. J Neurosurg Spine (2007) 0.80
Combined heart and liver transplantation in four adults with familial amyloidosis: experience of a single center. Transplant Proc (2004) 0.79
Long-term survival in a patient with AL amyloidosis after cardiac transplantation followed by autologous stem cell transplantation. Clin Res Cardiol (2006) 0.78
Role of high-dose melphalan and autologous peripheral blood stem cell transplantation in AL amyloidosis. Am J Blood Res (2012) 0.78
Cardiac amyloidosis: pathology, nomenclature, and typing. Cardiovasc Pathol (2015) 0.77
Efficacy of Chemotherapy for Light-Chain Amyloidosis in Patients Presenting With Symptomatic Heart Failure. J Am Coll Cardiol (2016) 0.77
Long term outcomes of cardiac transplant for immunoglobulin light chain amyloidosis: The Mayo Clinic experience. World J Transplant (2016) 0.77
The histopathology of gamma heavy-chain disease. Am J Clin Pathol (1982) 0.77
Cardiac transplantation should be considered in selected patients with either AL or hereditary forms of amyloidosis: the UK National Amyloidosis Centre experience. Intern Med J (2009) 0.77
Long-term outcome in patients treated with combined heart and liver transplantation for familial amyloidotic cardiomyopathy. Clin Transplant (2012) 0.77
Changing outcomes after heart transplantation in patients with amyloid cardiomyopathy. J Heart Lung Transplant (2014) 0.77
Genotype and Phenotype of Transthyretin Cardiac Amyloidosis: THAOS (Transthyretin Amyloid Outcome Survey). J Am Coll Cardiol (2016) 0.77
Cardiac Amyloid Load: A Prognostic and Predictive Biomarker in Patients With Light-Chain Amyloidosis. J Am Coll Cardiol (2016) 0.77
Genotype, echocardiography, and survival in familial transthyretin amyloidosis. Amyloid (2013) 0.76
Heart transplantation in patients with amyloidosis. Transplant Proc (2010) 0.76
Isolated heart transplantation for familial transthyretin (TTR) V122I cardiac amyloidosis. Amyloid (2014) 0.76
Current indications, strategies, and outcomes with cardiac transplantation for cardiac amyloidosis and sarcoidosis. Curr Opin Organ Transplant (2015) 0.76
Heart transplantation in primary amyloidosis. Rev Bras Cir Cardiovasc (2009) 0.76
A case report: isolated a heavy chain monoclonal gammopathy in a patient with polyneuropathy, organomegaly, endocrinopathy, monoclonal gammopathy and skin change syndrome. Int J Clin Pract Suppl (2005) 0.76
Does Survival on the Heart Transplant Waiting List Depend on the Underlying Heart Disease? JACC Heart Fail (2016) 0.75
Combined heart-liver transplantation: a single-center experience. Transpl Int (2015) 0.75
Cardiac amyloidosis: what are the indications for transplant? Curr Opin Cardiol (2012) 0.75
Prognostic stratification and treatment of cardiac light chain amyloidosis: a narrow path in the jungle. J Heart Lung Transplant (2013) 0.75